Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Patients and the Public Recognize and Thank Dedicated Nurses
    Nurse empowerment
    Patients and the Public Recognize and Thank Dedicated Nurses
    May 06, 2022
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    Cancer screening
    How to Promote and Maintain Cancer Screening as COVID-19 Persists
    March 18, 2022
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    Oncology nurse pride
    I’m a Match: My Journey From Advanced Practice BMT Nurse to Stem Cell Transplant Donor
    February 11, 2022
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    Oncology nurse pride
    Online and Mobile Resources Prepare Oncology Professionals for Care Delivery in All Settings
    January 31, 2022
    The Case of the Post-Transplant Pulmonary Problem
    Clinical practice
    The Case of the Post-Transplant Pulmonary Problem
    January 14, 2022
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • News & Views

    Clinical practice

    Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Cancers
    Clinical practice

    Genetic Disorder Reference Sheet: BRCA1 and BRCA2 Hereditary Cancers

    BRCA1- or BRCA2-associated hereditary breast and ovarian cancer is the most common form of hereditary breast and ovarian cancer. The prevalence of BRCA1 and BRCA2 pathogenic variants in the general population is estimated at 1 in 400–500 people, although it increases to 1 in 40 for those of Ashkenazi Jewish ancestry, which is linked to three founder pathogenic variants (BRCA1 c.68_69delAG, BRCA1c.5266dupC, and BRCA2 c.5946delT). 

    May 06, 2021
    FDA Grants Accelerated Approval to Pembrolizumab for HER2-Positive Gastric Cancer
    Clinical practice

    FDA Grants Accelerated Approval to Pembrolizumab for HER2-Positive Gastric Cancer

    On May 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pembrolizumab (Keytruda®) in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma.

    May 06, 2021
    Treatment side effects

    How to Handle Even the Worst Radiation Therapy Side Effects

    Some of the most painful side effects of cancer and its treatment occur with radiation therapy. Although patients may find the effects emotionally devastating, nurses can help take a proactive management approach by preparing patients for what’s ahead. Annette Quinn, RN, MSN, from the University of Pittsburgh Hillman Cancer Center, outlined the most common but distressing side effects and tips for managing them during a session held on April 29, 2021, for the 46th Annual ONS Congress™.

    April 29, 2021
    Time in Nature Is Time Well Spent
    Nurse well-being

    Time in Nature Is Time Well Spent

    “Nature alone cures,” Florence Nightingale instructed her fellow nurses in Notes on Nursing—and we’ve continued to follow that principle, creating a healing environment for our patients that involves fresh air and sunlight. That same environment can promote health in nurses as well.

    April 29, 2021
    Oncology Drug Reference Sheet: Relugolix
    Clinical practice

    Oncology Drug Reference Sheet: Relugolix

    On December 18, 2020, the U.S. Food and Drug Administration approved relugolix (OrgovyxTM) as the first oral hormone therapy for use in adult patients with advanced prostate cancer. 

    April 27, 2021
    FDA Grants Accelerated Approval to Loncastuximab Tesirine-Lpyl for Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Loncastuximab Tesirine-Lpyl for Large B-Cell Lymphoma

    On April 23, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to loncastuximab tesirine-lpyl (Zynlonta™), a CD19-directed antibody and alkylating agent conjugate, for adult patients with relapsed or refractory large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma, after two or more lines of systemic therapy.

    April 26, 2021
    FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Endometrial Cancer
    Oncology drug research

    FDA Grants Accelerated Approval to Dostarlimab-Gxly for dMMR Endometrial Cancer

    On April 22, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to dostarlimab-gxly (Jemperli), an anti-PD-1 antibody, for adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as determined by an FDA-approved test, that has progressed on or following treatment with a prior platinum-containing regimen.

    April 23, 2021
    Breast cancer

    HER2 Status Has Implications for Breast Cancer Treatment and Nursing Care

    Breast cancer is classified by several factors, including the presence of human epidermal growth factor receptor 2 (HER2), a type of growth-promoting protein found on the surface of cells. All breast cells have HER2 receptors, but some breast cancers have more HER2 receptors than normal, which may promote tumor growth. About 60% of breast cancers have some level of HER2 expression, and approximately one in five patients has high levels of the HER2 protein, which is considered HER2-positive.

    April 22, 2021
    ONS Congress

    Research Shows That Better Cancer Care Requires Listening—to Both Patients and Clinicians

    Oncology nursing research has a powerful impact on quality care and positive patient outcomes, but the science must be grounded in clinical context because researchers’ ultimate goal is to disseminate their findings to clinicians to facilitate practice change, ONS’s 2021 Distinguished Researcher Christopher Friese, PhD, RN, AOCN®, FAAN, of the University of Michigan and Rogel Cancer Center, said during his session for the 46th Annual ONS Congress™ on April 22, 2021.

    April 22, 2021
    FDA Announces Recall of BD Alaris Pump Module Model 8100 Because of Risk of Stuck or Unresponsive Keys
    U.S. Food and Drug Administration (FDA)

    FDA Announces Several New Recalls of BD Alaris Pump Module Model 8100 Because of Key and Bezel Problems

    On April 16, 2021, the U.S. Food and Drug Administration (FDA) reported Care Fusion 303, Inc.’s, recall of the BD Alaris Pump Module 8100 because the device may experience stuck or unresponsive keys during operation. FDA identified it as a class I recall, the most serious type of recall, where use of the devices may cause serious injuries or death.

    April 22, 2021
    The Case of the Transgender Considerations for Cancer Screening
    Patient Support

    The Case of the Transgender Considerations for Cancer Screening

    Sally, a nurse practitioner in a cancer survivorship clinic, is preparing to discuss screening and surveillance guidelines with Jonah, a 32-year-old survivor of Hodgkin lymphoma. Sally reviews Jonah’s patient history form and notes that Jonah uses he and him pronouns. His gender identity is male and sex assigned at birth was female. Jonah’s surgical history includes gender-affirming surgery on chest tissue (also known as top surgery), and his current medications include supplemental testosterone. Jonah also specifies that he is transmasculine—an umbrella term used to indicate that Jonah feels a connection with masculinity.

    April 20, 2021
    FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma
    Clinical practice

    FDA Approves Nivolumab in Combination With Chemotherapy for Metastatic Gastric Cancer and Esophageal Adenocarcinoma

    On April 16, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with fluoropyrimidine- and platinum-containing chemotherapy for advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

    April 19, 2021
    FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer
    Clinical practice

    FDA Grants Accelerated Approval to Sacituzumab Govitecan for Advanced Urothelial Cancer

    On April 13, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sacituzumab govitecan (Trodelvy®) for patients with locally advanced or metastatic urothelial cancer  who previously received a platinum-containing chemotherapy and either a programmed death receptor-1 or a programmed death-ligand 1 inhibitor.

    April 14, 2021
    Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer
    Adverse events

    Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer

    Once patients stop responding to platinum-based chemotherapy for locally advanced or metastatic urothelial cancer, their treatment options had been somewhat limited: PD-1/PD-L1 inhibitors were effective in only 13%–29% of patients and taxanes in only 11%–13%. When the antibody drug conjugate enfortumab vedotin was approved in late 2019, it offered new hope for patients and providers, with clinical trials reporting a 44% objective response rate.

    April 13, 2021
    Involve the Entire Cancer Care Team to Effectively Implement Guidelines
    Clinical practice guidelines

    Involve the Entire Cancer Care Team to Effectively Implement Guidelines

    Only 19% of strategies to implement clinical practice guidelines are fully effective and the majority (43%) are not effective at all, according to the findings from a clinical review in the European Union. Effective guideline implementation requires teamwork, interprofessional engagement, and selecting the most appropriate tool for the job. 

    April 12, 2021
    The Case of the Targeted Therapy Toxicity
    Genetics & genomics

    The Case of the Targeted Therapy Toxicity

    Tyrone is a 74-year-old man with a history of acute myeloid leukemia (AML), type 2 diabetes, and hypertension who was admitted to the hospital after lab results revealed 40% circulating blasts in his peripheral blood that was concerning for relapsed disease. He was diagnosed with AML three years ago and achieved remission after treatment with a hypomethylating agent. 

    April 09, 2021
    Nursing Considerations for Head and Neck Cancer Survivorship Care
    Survivorship

    Nursing Considerations for Head and Neck Cancer Survivorship Care

    Despite accounting for only 3% of all cancer survivors, patients with head and neck cancers often require significant support and survivorship care. And oncology nurses can expect survivorship to grow with recent improvements in prognosis and treatment options, such as with reductions in human papillomavirus-related oropharyngeal cancers, which tend to affect young people and offer improved long-term survival rates.

    April 08, 2021
    FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer
    Clinical practice

    FDA Approves Sacituzumab Govitecan for Triple-Negative Breast Cancer

    On April 7, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to sacituzumab govitecan (Trodelvy®) for patients with unresectable locally advanced or metastatic triple-negative breast cancer who received two or more prior systemic therapies, at least one of which for metastatic disease.

    April 08, 2021
    FDA Approves New Cetuximab Dosing Regimen for Colorectal Cancer and Squamous Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves New Cetuximab Dosing Regimen for Colorectal Cancer and Squamous Cell Carcinoma

    On April 6, 2021, the U.S. Food and Drug Administration (FDA) approved a new dosage regimen for cetuximab (Erbitux®) of 500 mg/m2 via IV infusion for 120 minutes every two weeks for patients with KRAS wild-type, epidermal growth factor receptor-expressing colorectal cancer or squamous cell carcinoma of the head and neck.

    April 07, 2021
    FDA Issues Safety Communication for ADM Products Used in Implant-Based Breast Reconstruction
    Clinical practice

    FDA Issues Safety Communication for ADM Products Used in Implant-Based Breast Reconstruction

    On March 31, 2021, the U.S. Food and Drug Administration (FDA) issued a safety communication informing patients, caregivers, and healthcare providers that certain acellular dermal matrix (ADM) products used in implant-based breast reconstruction may have a higher chance for complications or problems.

    April 07, 2021
    FDA Approves Isatuximab-Irfc for Multiple Myeloma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Isatuximab-Irfc for Multiple Myeloma

    On March 31, 2021, the U.S. Food and Drug Administration (FDA) approved isatuximab-irfc (Sarclisa®) in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. 

    April 01, 2021
    Oncology Drug Reference Sheet: Decitabine and Cedazuridine
    Cancer treatments

    Oncology Drug Reference Sheet: Decitabine and Cedazuridine

    In July 2020, the U.S. Food and Drug Administration approved decitabine and cedazuridine (Inqovi®) tablets for the treatment of adults with myelodysplastic syndromes. 

    March 30, 2021
    FDA Approves Idecabtagene Vicleucel as the First Cell-Based Gene Therapy for Adult Patients With Multiple Myeloma
    Clinical practice

    FDA Approves Idecabtagene Vicleucel as the First Cell-Based Gene Therapy for Adult Patients With Multiple Myeloma

    On March 27, 2021, the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. 

    March 30, 2021
    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection
    Clinical practice

    Zydus Pharmaceuticals Inc. Issues Voluntary Nationwide Recall of Acyclovir Sodium Injection

    On March 25, 2021, the U.S. Food and Drug Administration shared Zydus Pharmaceuticals Inc.’s notice of its voluntary recall of four lots of acyclovir sodium injection 50 mg/ml, supplied in 10 ml and 20 ml vials, after receiving reports of crystallization in the product.

    March 29, 2021
    The Case of the Cord Blood Match
    Clinical practice

    The Case of the Cord Blood Match

    Zhang is a 67-year-old man who had no history of medical concerns until he was hospitalized for pneumonia. A complete blood count taken during his workup for pneumonia showed pancytopenia, and a biopsy confirmed a diagnosis of acute myeloid leukemia. After multiple rounds of induction therapy, Zhang's bone marrow biopsy showed minimal residual disease and he entered remission. His oncologist recommends an allogeneic hematopoietic stem cell transplant as soon as possible because of the disease's aggressive nature, but he has no match in the registry. 

    March 26, 2021
    Infection Prevention for Oncology Nurses
    Clinical practice

    Infection Prevention for Oncology Nurses

    Regardless of care setting, oncology nurses must be vigilant about creating a safe environment for and educating patients about the importance of infection prevention. Patients with cancer are at increased risk for viral, bacterial, and fungal infections, but the extent depends on cancer type and treatment. 

    March 25, 2021
    Diabetes May Increase Hematologic Cancer Risk and Mortality
    Cancer risk factors

    Diabetes May Increase Hematologic Cancer Risk and Mortality

    Having diabetes increases a person’s risk for developing leukemia, lymphoma, or multiple myeloma—and their risk for dying from the cancer should it occur, researchers reported in Diabetologia.

    March 24, 2021
    Genetic Disorder Reference Sheet: CHEK2 Gene Pathogenic Variants
    Genetics & genomics

    Genetic Disorder Reference Sheet: CHEK2 Gene Pathogenic Variants

    The CHEK2 (checkpoint kinase 2) tumor suppressor gene provides cells with instructions for making a protein known as CHK2, which becomes active when the cell’s DNA is damaged or strands of it break. CHEK2 halts cell division and enables either cell repair or destruction. Without a properly functioning CHEK2 gene, cells lose a key restraint on their growth which may lead to uncontrolled cells and possibly malignancy. CHEK2*1100delC is the most common pathogenic variant and most prevalent in European populations.

    March 23, 2021
    FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Pembrolizumab for Esophageal or GEJ Carcinoma

    On March 22, 2021, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda®) for use in combination with platinum- and fluoropyrimidine-based chemotherapy for patients with metastatic or locally advanced esophageal or gastroesophageal junction (GEJ) (tumors with an epicenter 1–5 cm above the gastroesophageal junction) carcinoma who are not candidates for surgical resection or definitive chemoradiation. 

    March 23, 2021
    FDA Advises Healthcare Professionals Not to Use BD’s ChloraPrep™ 3 ml Applicators
    U.S. Food and Drug Administration (FDA)

    FDA Advises Healthcare Professionals Not to Use BD’s ChloraPrep™ 3 ml Applicators

    On March 19, 2021, the U.S. Food and Drug Administration (FDA) issued an advisory to healthcare professionals not to use ChloraPrep 3 ml applicators manufactured by BD (Becton, Dickinson and Company) because of the risk of microbial contamination. The product was distributed globally and is labeled with “CareFusion, El Paso, TX.”

    March 23, 2021
    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors
    Advanced practice nursing (APN)

    Management Strategies for Cutaneous Toxicity From EGFR Inhibitors

    Epidermal growth factor receptor (EGFR)-targeted therapy is effective for several solid tumor malignancies, primarily non-small cell lung cancer with EGFR mutation and metastatic colorectal cancer. Although the agents spare patients from typical side effects seen with more conventional cytotoxic chemotherapies, such as nausea or vomiting, they do have a unique side-effect profile, including potentially dose-limiting cutaneous toxicity. 

    March 11, 2021
    FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma
    Oncology drug research

    FDA Approves Tivozanib for Relapsed or Refractory Advanced Renal Cell Carcinoma

    On March 10, 2021, the U.S. Food and Drug Administration (FDA) approved tivozanib (Fotivda®), a kinase inhibitor, for adult patients with relapsed or refractory advanced renal cell carcinoma following two or more prior systemic therapies. FDA approved the application three weeks ahead of its goal date.

    March 11, 2021
    FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma

    On March 5, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to axicabtagene ciloleucel (Yescarta®) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.

    March 09, 2021
    FDA Approves Lorlatinib for ALK-Positive Metastatic NSCLC
    Lung Cancer

    FDA Approves Lorlatinib for ALK-Positive Metastatic NSCLC

    On March 3, 2021, the U.S. Food and Drug Administration (FDA) granted regular approval to lorlatinib (Lorbrena®) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive, as detected by an FDA-approved test. FDA also approved the Ventana ALK (D5F3) CDx Assay as a companion diagnostic for lorlatinib.

    March 04, 2021
    Nursing Considerations for Colorectal Cancer Survivorship Care
    Survivorship care plans

    Nursing Considerations for Colorectal Cancer Survivorship Care

    As the third most common cancer among both men and women, colorectal cancer is a reality for the more than 1 million people in the United States who are living with or have a history of the disease. Advancements in early detection and treatment have improved outcomes, but many survivors experience late and long-term side effects that may vary in duration, intensity, and impact on their quality of life. Clinicians must tailor each survivorship care plan for a patient’s cancer type, stage, treatment received, psychosocial implications, and side effects or toxicities. Studies have shown that experiencing long-term side effects and symptoms can reduce survivors’ quality of life. 

    March 04, 2021
    FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma
    Clinical practice

    FDA Grants Accelerated Approval to Melphalan Flufenamide for Relapsed or Refractory Multiple Myeloma

    On February 26, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to melphalan flufenamide (Pepaxto®) in combination with dexamethasone for adults with relapsed or refractory multiple myeloma who received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38–directed monoclonal antibody.

    March 01, 2021
    Self-Care Is Essential When Working Remotely
    Nurse well-being

    Self-Care Is Essential When Working Remotely

    Did you ever imagine that you could do your job remotely? I did not, but that’s what I’m doing right now. Working remotely has become the new normal for certain professional roles, including some in nursing. An estimated 31% of new hires since March 2020 work from home. In February 2020, the Centers for Disease Control and Prevention released social distancing guidelines and recommended the use of telehealth for patient visits. In March 2020, telehealth visits increased 154% compared to March 2019. Working at home has affected both healthcare workers and patients.

    February 25, 2021
    FDA Approves Cemiplimab-Rwlc for NSCLC With High PD-L1 Expression
    Clinical practice

    FDA Approves Cemiplimab-Rwlc for NSCLC With High PD-L1 Expression

    On February 22, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo®) for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation and whose tumors have high PD-L1 expression (tumor proportion score ≥ 50%) as determined by an FDA-approved test, with no estimated aberrations to glomerular filtration rate, anaplastic lymphoma kinase, or receptor tyrosine kinase (encoded by the ROS1 gene). 

    February 23, 2021
    Be Alert for Axillary Adenopathy After COVID-19 Vaccination
    COVID-19

    Be Alert for Axillary Adenopathy After COVID-19 Vaccination

    Nearly 60 million people in the United States and almost 200 million around the world have received the COVID-19 coronavirus vaccine as of mid-February 2021, and the numbers will continue to grow as more doses come to market and other manufacturers’ versions receive emergency use authorizations. As more people get vaccinated, some of the expected side effects are being observed in clinical practice and have implications for cancer care. 

    February 19, 2021
    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression
    Chemotherapy

    FDA Approves Trilaciclib to Reduce Chemotherapy-Induced Myelosuppression

    On February 12, 2021, the U.S. Food and Drug Administration (FDA) approved trilaciclib (Cosela™) as the first therapy in its class to reduce the frequency of chemotherapy-induced myelosuppression in adults receiving certain types of chemotherapy for extensive-stage small cell lung cancer. Trilaciclib inhibits cyclin-dependent kinase 4/6 (CDK 4/6) enzymes to prevent bone marrow damage.   

    February 15, 2021
    Inclusion in National Repository Helps Move ONS Guidelines™ Evidence to Practice
    Clinical practice guidelines

    Inclusion in National Repository Helps Move ONS Guidelines™ Evidence to Practice

    When they launched in 2020, oncology nurses recognized the first five ONS Guidelines™ for cancer treatment-related symptoms and adverse events as the evidence-based standard for patient care. Now, the ECRI Guidelines Trust, a national evaluation organization, has given them that distinction as well, including all of ONS’s current guidelines in its repository.

    February 15, 2021
    FDA Approves Cemiplimab-Rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Cemiplimab-Rwlc for Locally Advanced and Metastatic Basal Cell Carcinoma

    On February 9, 2021, the U.S. Food and Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo®) for use in patients with locally advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. FDA also granted accelerated approval to cemiplimab-rwlc for patients with metastatic BCC previously treated with an HHI or for whom an HHI is not appropriate. 

    February 10, 2021
    FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma
    U.S. Food and Drug Administration (FDA)

    FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Large B-Cell Lymphoma

    On February 5, 2021, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified—including DLBCL arising from indolent lymphoma—high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.

    February 10, 2021
    Nursing Considerations for Lymphoma Survivorship Care
    Survivorship

    Nursing Considerations for Lymphoma Survivorship Care

    As treatments have advanced and patients and providers have more options, cure and survivorship rates for lymphomas are improving: five-year survival rates for Hodgkin and non-Hodgkin lymphoma are 86% and 71%, respectively. Despite good results from treatment, research indicates that lymphoma survivors carry a significant amount of late and chronic effects. Even in a complete remission, late effects of treatment present a burden for patients' physical and psychosocial well-being.

    February 04, 2021
    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC
    U.S. Food and Drug Administration (FDA)

    FDA Grants Accelerated Approval to Tepotinib for Metastatic NSCLC

    On February 3, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tepotinib (Tepmetko®) for adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition exon 14 skipping alterations.

    February 03, 2021
    Oncology Drug Reference Sheet: Tafasitamab-Cxix
    Oncology drug research

    Oncology Drug Reference Sheet: Tafasitamab-Cxix

    Tafasitamab-cxix (Monjuvi®) received accelerated approval from the U.S. Food and Drug Administration in July 2020 in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma.

    January 26, 2021
    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)
    Genetics & genomics

    Genetic Disorder Reference Sheet: Lynch Syndrome (Hereditary Nonpolyposis Colorectal Cancer)

    Lynch syndrome, now referred to as hereditary nonpolyposis colorectal cancer (HNPCC), was first identified in a family in 1895. In 1966, Henry Lynch reported a series of families with colon and other cancers in the Nebraska area. Today, the evidence shows that HNPCC is associated with germline pathogenic variants in the MLH1, MSH2, MSH6, PMS2, and EPCAM genes.

    January 25, 2021
    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma
    Cancer treatments

    FDA Approves Nivolumab Plus Cabozantinib for Advanced Renal Cell Carcinoma

    On January 22, 2021, the U.S. Food and Drug Administration (FDA) approved nivolumab (Opdivo®) in combination with cabozantinib (Cabometyx®) as first-line treatment for patients with advanced renal cell carcinoma.

    January 25, 2021
    The Case of the Targeted Therapy Toxicities
    Clinical practice

    The Case of the Targeted Therapy Toxicities

    Three years ago, Tony, a 42-year-old man, began FOLFOX chemotherapy treatment for stage III colon cancer and achieved a complete response. Two years later, a biopsy of an intraabdominal lesion uncovered metastatic disease, and he was prescribed the epidermal growth factor inhibitor (EGFRi) cetuximab. Alex, the oncology nurse educating Tony on the side effects of EGFRi therapy, understands that skin toxicities are common with the class of drugs and looks for national guidelines for prevention and management direction.

    January 19, 2021
    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma
    Cancer treatments

    FDA Approves Crizotinib for Children and Young Adults With Relapsed or Refractory, Systemic ALK-Positive Anaplastic Large Cell Lymphoma

    On January 14, 2021, the U.S. Food and Drug Administration (FDA) approved crizotinib (Xalkori®) for pediatric patients aged one year or older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is anaplastic lymphoma kinase (ALK) positive. The safety and efficacy of crizotinib have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. 

    January 15, 2021
    • First page « First
    • Previous page
    • Page 1
    • Page 2
    • Page 3
    • Page 4
    • Current page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • COVID-19
    • Drug Reference Sheet
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Health Policy
    • Immunotherapy
    • Cancer research
    View All Topics
     
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Newsroom
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2022 Oncology Nursing Society
     
    Back to Top ▲